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Drug-target interaction (DTI) prediction plays a very important role in drug development
and drug discovery. Biochemical experiments or in vitro methods are very expensive, labori-
ous and time-consuming. Therefore, in silico approaches including docking simulation and
machine learning have been proposed to solve this problem. In particular, machine learn-
ing approaches have attracted increasing attentions recently. However, in addition to the
known drug-target interactions, most of the machine learning methods require extra char-
acteristic information such as chemical structures, genome sequences, binding types and so
on. Whenever such information is not available, they may perform poor. Very recently, the
similarity-based link prediction methods were extended to bipartite networks, which can be
applied to solve the DTI prediction problem by using topological information only. In this
work, we propose a method based on low-rank matrix projection to solve the DTI predic-
tion problem. On one hand, when there is no extra characteristic information of drugs or
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targets, the proposed method utilizes only the known interactions. On the other hand, the
proposed method can also utilize the extra characteristic information when it is available and
the performances will be remarkably improved. Moreover, the proposed method can predict
the interactions associated with new drugs or targets of which we know nothing about their
associated interactions, but only some characteristic information. We compare the proposed
method with ten baseline methods, e.g., six similarity-based methods that utilize only the
known interactions and four methods that utilize the extra characteristic information.
1 Introduction
Developing a new drug to the market is very costly and usually takes too much time 1, 2. Therefore,
in order to save time and cost, scientists have tried to identify new uses of existing drugs, known
as drug repositioning. Moreover, predicting these interactions between drugs and targets is one
of the most active domains in drug research since they can help in the drug discovery 3–5, drug
side-effect 6, 7 and drug repositioning 8–11. Currently, the known interactions between drugs and
target proteins are very limited 12, 13, while it is believed that any single drug can interact with
multiple targets 14–17. However, laboratory experiments of biochemical verification on drug-target
interactions are extremely expensive, laborious and time-consuming 18–20 since there are too many
possible interactions to check. Thanks to the increasing capability to collect, store and process
large-scale chemical and protein data, in silico prediction of the interactions between drugs and
target proteins becomes an effective and efficient tool for discovering the new uses of existing
drugs. The prediction results provide helpful evidences to select potential candidates of drug-
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target interactions for further biochemical verification, which can reduce the costs and risks of
failed drug development 21, 22.
There are two major approaches in in silico prediction, including docking simulation and
machine learning 23. Docking simulation is a common method in biology, but it has two major
limitations. Firstly, this method requires three-dimensional structures of targets to compute the
binding of each drug candidate 24–26, but such kind of information is usually not available 27, 28.
Secondly, it is very time-consuming. Therefore, in the last decade, many efforts have been made to
solve the DTI prediction problem by machine learning approaches 23, 29, 30. Most known machine
learning methods 31–33 treat DTI prediction as a binary classification prediction in which the drug-
target interactions are regarded as instances and the characteristics of the drugs and target proteins
are considered as features. To train the classifier, machine learning methods require label data,
e.g., positive samples of truly existing interactions and negative samples of noninteractive pairs.
Normally, the positive samples are available, but the negative samples are not known.
Whenever extra characteristic information about the drugs and targets are not available and
only a portion of interactions between drugs and targets are known, similarity-based methods are
suitable to solve this problem. However, there are also some limitations of the similarity-based
methods. Firstly, similarity-based methods are not applicable for new drugs or targets that do not
have any interactions at all since the methods cannot compute their similarities with the others.
Secondly, although similarity-based methods are simple, sometimes they do not perform well 34
since common neighbor and Jaccard indices, Cannistraci resource allocation (CRA) 35 and Cannis-
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traci Jaccard index (CJC) 35 utilize only local information of networks. Katz index also performs
unsatisfactorily (will show later) since the large decay factor will bring redundant information 36,
while the small decay factor makes Katz index close to common neighbor index or local path index
37, 38.
To overcome the limitations of machine learning methods and similarity-based methods, we
propose a matrix-based method, namely low-rank matrix projection (LMP). LMP does not require
negative samples. When the extra characteristic information of drugs and target proteins are not
available, LMP utilizes only the known interactions. On the other hand, if the extra information
is available, LMP can also take such information into consideration and remarkably improve the
performances. LMP has been shown to perform better than similarity-based methods on the five
renown datasets (e.g., MATADOR, enzyme, ion channel, GPCR and nuclear receptor). By embed-
ding extra information of drugs and targets, LMP has been shown to outperform many baseline
methods that also use extra information. Finally, LMP can effectively predict the potential interac-
tions of new drugs or targets that do not have any known interactions at all. The proposed method
can help selecting the most likely existing interactions for further chemical verifications in case
only interaction information is known or only some of characteristic information is available. In a
word, LMP can reduce cost and failure in drug development, and thus advance drug discoveries.
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Figure 1: The illustration of the proposed method. Firstly, the known drug-target interactions are
utilized to construct the adjacency matrix A. Secondly, A is decomposed into a low-rank matrix
X
∗ and a sparse matrix E∗, which can be used to depict the hidden pattern and the noise in the
original data. Finally, the score matrix is computed by projecting the adjacency matrix onto a
lower-dimensional space via the low-rank matrixX∗.
2 Methods
Notations In this work, various matrices and their similarity matrices are computed by the pro-
posed method based on the characteristic information of the biological data. We denote them as
follows:
• A: the adjacency matrix denoted the known interactions between drugs and proteins and its
entries are defined as in Eq. (1).
• X∗D: the low-rank similarity matrix computed based on drug information in A, i.e., similar
drugs interact with similar targets.
• X∗T : the low-rank similarity matrix computed based on target information of A
T (transpose
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ofA), i.e., similar targets is interacted by similar drugs.
• ZAD: the score matrix obtained from the projection ofA ontoX
∗
D.
• ZAT : the score matrix obtained from the projection ofA ontoX
∗
T .
• ZA: the score matrix computed by combining ZAD and ZAT .
• SD: the similarity matrix of drug compound computed by SIMCOMP
40 from the chemical
structures of drugs which are obtained from KEGG LIGAND 13.
• X∗SD: the low-rank similarity matrix computed by the proposed method on SD.
• ZD: the score matrix obtained by projectingA onX
∗
SD.
• ST : the similarity matrix of protein sequences computed by a normalized Smith-Waterman
score 41 from GEGG GENES 13.
• X∗ST : the low-rank similarity matrix computed by the proposed method on ST .
• ZT : the score matrix obtained by projectingA onX
∗
ST .
• ZADT : the score matrix computed by combining ZA, ZD and ZT .
Datasets In this work, we implement the proposed method as well as similarity-based methods on
five benchmark and renown datasets namely MATADOR 42, enzyme 29, ion channel 29, G-protein-
coupled receptors (GPCR) 29, and nuclear receptors 29. The manually annotated target and drug
online resource (MATADOR) (May 2017) dataset is a free online dataset of chemical and target
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protein interactions. There are 13 columns in the dataset, however, we utilize only two columns,
including Chemical ID and Protein ID, to construct the adjacency matrix. MATADOR dataset has
no characteristic information about the drugs and targets. Enzyme, ion channel, GPCR, and nuclear
receptors (May 2017) are the drug-target interaction networks for human beings. The statistics of
the five datasets are presented in table 1.
Low-Rank Matrix Projection In the real-world problems, many data that are lying on the high-
dimensional space and full of noise normally contain hidden features which can be seen after they
are projected onto the lower dimensional space and simultaneously the noise are subtracted from
them 43. Low-rank matrix has been shown to be a powerful and suitable tool to capture the patterns
in high dimensional-space and noisy data 44–46. Therefore, it is deserved to be investigated to
solve DTI problem. In this section we assume that only known interactions between drugs and
targets are available so we aim at learning the low-rank matrix from this interaction information.
First of all, we construct the adjacency matrices of the drug-target interactions in the five datasets.
Mathematically, the adjacency matrix is defined as
Aij =


1, if drug i interacts with target j
0, otherwise
. (1)
Then we obtainA ∈ Rm×n, wherem is the number of drugs and n is the number of target proteins.
The real data are normally far from perfect, meaning that a portion of the drug-target inter-
actions in the real data may be incorrect or redundant, and also some other drug-target interactions
may be missing from the observed data. Therefore, the adjacency matrix A can be decomposed
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into two parts. The first part is a linear combination ofA with the low-rank matrix, which is essen-
tially a projection from the noisy dataA into a more refined or informative and lower-dimensional
space. The second part can be considered as the noise or the outliers, which is strained off from
the original dataA and represented by a sparse matrix with most entries being zeros. The method
seeks the lowest-rank matrix among all the candidates which is further utilized to construct the
score matrix that estimates the likelihoods of the potential interactions.
Firstly, we decomposeA as follows,
A = AX+ E. (2)
Obviously, there are infinite solutions of Eq. (2). However, since we wishX to be low-rank, where
rank of a matrix is the maximum number of linearly independent column (or row) vectors in the
matrix, and E to be sparse, we can enforce the nuclear norm or trace norm onX and sparse norm
on E. Mathematically, Eq. (2) can be thus relaxed as
min
X,E
||X||∗ + α||E||2,1 s.t. A = AX+ E, (3)
where ||A||∗ =
∑
i σi (i.e., σi is the singular values of A), ||E||2,1 =
∑n
j=1
√∑m
i=1(Eij)
2 is the
noise regularization strategy and α is a positive free parameter taking a role to balance the weights
of low-rank matrix and sparse matrix. Minimizing the trace norm of a matrix well favors the
lower-rank matrix, meanwhile the sparse norm is capable of identifying noise and outliers.
Eq. (3) can also be regarded as a generalization of the robust PCA 47, 48 because if the matrix
A in AX in the right side of Eq. (3) is set as identity matrix, then the model is degenerated to the
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robust PCA. Eq. (3) can be rewritten into an equivalent problem as,
min
X,E,J
||J||∗ + α||E||2,1 s.t. A = AX+ E,X = J. (4)
Eq. (4) is the constraint and convex optimization problem which can be solved by many off-the-
self methods, e.g., iterative method (IT) 49, accelerated proximal gradient (APG) 46, dual approach
50, and augmented Lagrange multiplier (ALM) 44. In this work, we employ Inexact ALM method
by firstly converting Eq. (4) to an unconstraint problem, then minimize this problem by utilizing
augmented Lagrange function such that
L = ||J||∗ + α||E||2,1 + tr
(
Y
T
1
(A−AX−E)
)
+
tr
(
Y
T
2
(X− J)
)
+
µ
2
(
||A−AX− E||2F + ||X− J||
2
F
)
,
(5)
where µ ≥ 0 is a penalty parameter and tr(.) is the trace norm. The Eq. (5) is unconstraint and
can be solved by minimizing with respect to J,X and E, respectively, by fixing the other variables
and then updating the Lagrange multipliers Y1,Y2. The detailed illustration of how to solve Eq.
(5) is shown in table 2.
We denote the solution of Eq. (5) as X∗T , if Aij represents the interaction drug i and protein
j, then X∗T ∈ R
n×n. It can be considered as a similarity matrix that describes similarity between
proteins. While ifAij represents the interactions between protein i and drug j (as the transposition
of the adjacency matrix in Eq. (2)), then the solution of Eq. (5) is denoted as X∗D ∈ R
m×m which
describes similarity between drugs. After obtaining these two similarity matrices, we project the
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adjacency matrixA onto these lower dimensional spaces, respectively, as
ZAD = A
T
X
∗
D and ZAT = AX
∗
T . (6)
Finally, we combine the two similarity matrices as
ZA =
Z
T
AD + ZAT
2
. (7)
After obtaining ZA, we remove the known interactions by setting the entries of ZA cor-
responding to nonzero entries in A to zeros and sort the remaining scores in descending order.
The drugs-target pairs with highest scores are the most likely unknown interacting pairs. The full
process of the proposed method is illustrated in Fig. 1. The algorithm 1 illustrates the detailed
procedure of the proposed method LMP.
Working with Heterogeneous Data Using only interaction dataset and ignoring the extra char-
acteristic information of the drugs and targets is throwing away the important information. In this
subsection, we show how the proposed method is capable of utilizing this characteristic informa-
tion. Based on the hypothesis that similar drugs interact with similar targets and vice versus, we
can utilize the two kinds of characteristic information, namely drug similarity and target similarity
to infer the potential interactions.
Drug similarity SD was computed by using SIMCOMP
40 from the chemical structures of
drugs which are obtained from KEGG LIGAND 13. On the other hand, target similarity ST is
computed by using a normalized Smith-Waterman score 41 from GEGG GENES 13. These two
datasets are available online 29. Directly using these two similarity datasets makes the proposed
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method perform unsatisfactorily since there exist some noise inside these two datasets. Therefore,
we compute the new similarity matrices which are low-rank from these two similarity matrices by
the proposed method, then projecting the adjacency matrix onto these lower-dimensional spaces.
There are two main properties of this low-rank matrix learning from the characteristic informa-
tion. Firstly, as discussed above the noise are subtracted. Moreover, the interaction information is
projected on the lower-dimensional feature space which is more informative.
The low-rank similarity matrices of the characteristic information SD and ST can be com-
puted as shown in Eq. (3) by replacing the adjacency matrix A with SD and ST , respectively.
After obtaining the low-rank similarity matrices of the drug and target denoted as X∗SD and X
∗
ST ,
we project the adjacency matrix A onto them as shown in Eq. (6) and we call them the score
matrices denoted as ZD and ZT , respectively. Finally, we combine all these three score matrices
which are ZA, ZD and ZT as
ZADT = γ1ZA + γ2Z
T
D + γ3ZT , (8)
where γ1, γ2 and γ3 are the weighting parameters and are set to 0.5, 0.25 and 0.25, respectively.
Since the known interactions are experimentally verified, the similarity matrix obtained from this
information plays more important role than the other two similarity matrices. The algorithm of the
proposed method is illustrated in table 3.
Predicting the New Drugs and Targets In case that there are new drugs or targets which do not
have any known interactions at all, the proposed method can also be simply extended to predict
their interactions. However, we need to use the characteristic information about the new drugs
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or new targets. On one hand, once we are given a drug with characteristic information, we wish
to predict which target proteins that this drug interactions with. On the other hand, we aim at
predicting the new drugs based on the known protein target by using the characteristic information
of the target proteins. Consider predicting new targets, first of all, one needs to compute the
low-rank similarity matrix of the given drug with others based on their characteristic information,
i.e., computing X∗SD. With the assumption that similar drugs interact with similar targets, we
can predict the potential interactions based on this similarity matrix, i.e., projecting A onto X∗SD.
Similarly, when a new target is given with its biological information, one can compute the low-rank
similarity matrix, i.e., X∗ST , of that protein with the others. The potentially interacted drugs with
this protein are those that interact with proteins that are most similar to the given protein.
Evaluation and Experimental Settings We adopt a cross validation technique and two popular
metrics to test the proposed method as well as previous benchmarks. We apply the 10-fold cross
validation 23, 51, which divides the total known interactions between the chemicals and proteins
into 10 sets with approximately the same size, and then utilize 9 sets as training data and keep the
remaining set as testing data. We repeat it for ten times where each set has one chance to be the
testing set. In the simulation, we independently run the 10-fold cross validation for five times and
report average values accordingly.
We consider the two popular metrics, including the area under the receiver operating char-
acteristic (ROC) curve (AUC) and the area under precision and recall curve (AUPR), to evaluate
the performances of the proposed method and the benchmarks. ROC is the diagnostic ability of
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a binary classifier with regarding to different thresholds 52, while AUC curve displays true posi-
tive rate (sensitivity) versus false positive rate (1-specificity) at different values of thresholds. The
sensitivity is the percentage of the test samples with ranks higher than a given threshold, whereas,
specificity is the percentage the test samples that fall below the threshold. When there are many
fewer positive elements in the testing data comparing to the total number in testing data, AUC may
give overoptimistic results of the algorithms 30, 53–55. Therefore, utilizing only AUC may mislead
our conclusion. In such case, AUPR can give better evaluation, especially in biological signifi-
cance.
The simulations are conducted within three manners, e.g., drug-target pairs, new drugs, and
new targets. In the first manner, we divide the total known interactions into 10-folds with approx-
imately the same size. On the other hand, in the second manner we divide the total drugs into
10-folds. For the last manner, all the targets are divided into 10-folds. In each simulation, we use
9 sets as training data and keep the remaining as testing data.
Baseline Methods First, we compare LMP with the similarity-based methods, e.g., common
neighbor index (CN), Katz index and Jaccard index, Cannistraci resource allocation (CRA) 35
and Cannistraci Jaccard index (CJC) 35. In this comparison, we use only the known interactions
of drug and targets. The methods that utilize both interaction information and characteristic in-
formation normally outperform the methods that utilize only the known interactions. However,
they cannot work with the dataset that do not have characteristic information such as MATADOR.
We further compare LMP with bipartite local learning model (BLM) 30, Laplacian regularized least
13
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Figure 2: The AUPR of the proposed method on the four datasets. Panel A illustrates the predicted
results on the new drugs, while panel B displays the predicted results on the new targets.
squares (LapRLS) and Net Laplacian regularized least squares (NetLapRLS) 39 which utilizes both
the known interaction information and characteristic information about the drugs and targets. The
first group of methods can only predict the interactions between drugs and targets, meanwhile the
second group can predict the new drugs given targets or predict the new targets given drugs by
using their characteristic information.
Parameter Settings In the proposed method, there is a free parameter α that balances the weights
of low-rank matrix and sparse matrix as shown in Eq. (3). When α is set too large, the sparse
norm will compress most of the entries of matrix E to zeros, while if α is very small, most of the
entries of E will be small but not zeros. In this work, we obtain the optimal value of the parameter
α by manually and empirically tuning it and check the accuracy according to each value of α.
Predicting the interactions based on only the known interaction, we perform the grid search for
α in which one dimension is corresponding to drug similarity and another one is corresponding
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to target similarity. Based on the empirical simulation, α for predicting the interactions based on
only known interactions falls between [0.1,0.25]. When characteristic information is embedded,
one needs to tune α according to this information, e.g., the parameter α falls between [0.1,2].
Moreover, there is only one α in each case, eg., predicting the new drugs or targets. We visualize
the sensitivity of α corresponding to the predicted results, i.e., AUPR, on the new drugs and targets,
in Fig. 2.
3 Results
We report the performances of the proposed method and the others that use only the known inter-
action information in the first part of table 4, meanwhile for the performances of the methods that
use together interaction information and characteristic information are shown in the second part
of the same table. Consider the first group of the methods. LMP outperforms the other methods
on three datasets including MATADOR, GPCR, and ion channel in terms of AUC and AUPR. In
term of AUPR, LMP outperforms the others in enzyme, while LMP outperforms only Katz index
in enzyme in term of AUC. It is worth noting that for the small matrix or network such as nuclear
receptor, the predicted results from all the methods are not stable and they are approximately the
same.
When the characteristic information of the drugs and targets are employed, the performances
of the LMP remarkably improved as shown in the second part of table 4. Since the characteristic
information of the drugs and targets in MATADOR is not available, we either cannot obtain the
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results of this dataset. LMP outperforms the others on nuclear receptor and GPCR in term of AUC,
while NetLapRLS is the best in term of AUPR on nuclear receptor. LMP perform better than the
others measured by AUPR in GPCR and ion channel. LMP outperforms the others in term of AUC,
while NetLapRLS produces the highest AUPR on enzyme.
The predicted results on the new drugs and target proteins are illustrated in table 5 in the first
and second part, respectively. All the methods produce competitive results in predicting the new
drugs, while LMP outperform the others in term of AUC and AUPR on GPCR, ion channel and
enzyme in predicting new targets.
4 Conclusion and discussion
In this work, we have proposed a matrix-based method, namely low-rank matrix projection (LMP),
to solve the DTI prediction problem. It has been shown that LMP overcomes the drawbacks of the
machine learning and similarity-based methods. On one hand, LMP can work on datasets that
have only known interaction information between the drugs and targets such as MATADOR. On
the other hand, LMP can integrate the information about the characteristics of the drugs and targets
to improve the predicted results. Moreover, the proposed method can also effectively deal with
the new drugs and targets that do not have any known interaction at all by utilizing only some
characteristic information of the drugs or targets.
In LMP, the low-rank matrix plays a very important role in making the data homogenous,
meanwhile the sparse matrix captures the noise or outliers in the data. By decomposing the original
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data into a clean (a linear combination of low-rank matrix and the adjacency matrix) and noise
(sparse matrix) parts, we can obtain a clean data to predict the interactions between drugs and
target proteins. The disadvantage of LMP is that we need to empirically tune α and check the
accuracy corresponding to each value of α. Until now, designing the effective method to estimate
the optimal value of this parameter is still an open question. Moreover, LMP may not perform
well with small matrix, e.g., nuclear receptor, since the information is very limited for matrix
decomposition.
LMP is an alternative, effective and efficient in silico tool for predicting the drug-target
interactions. It can help drug development and drug reposition. In this paper, LMP aims at learning
the low-rank similarity matrices from the known drug-target interaction information and similarity
matrices of the drugs and targets. We believe that the proposed method can also be applied to learn
other high-dimensional biological data such as drug compound, chemical structures, and so on,
and we leave these problems to the future work.
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Table 1: The statistics of the five datasets.
Dataset Drug Target Interaction Sparsity of A
MATADOR 801 2901 15843 0.007
enzyme 445 664 2926 0.010
ion channel 210 204 1476 0.034
GPCR 223 95 635 0.030
nuclear receptors 54 26 90 0.061
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Table 2: The illustration of the Inexact ALM algorithm
Algorithm 1: Solving problem of Eq. (5) by Inexact ALM
Input: Given a dataset A parameters α
Output: X∗ and E∗
Initialize: X = 0,E = 0,Y1 = 0,Y2 = 0, µ = 10
−4, maxµ = 10
10, ρ = 1.1, ǫ = 10−8
while not converged do
1. fix the other and update J by
J = argmin 1
µ
||J||∗ +
1
2
||J− (X+Y
2
/µ)||2F
2. fix the other and update X by
X = (I+ATA)−1
(
A
T
A−ATE+ J+ (ATY1 −Y2)/µ
)
3. fix the other and update E by
E = argmin α
µ
||E||2,1 +
1
2
||E − (A−AX+Y
1
/µ)||2F
4. update the multiplier
Y1 = Y1 + µ(A−AX−E)
Y2 = Y2 + µ(X− J)
5. update parameter µ by
µ = min(ρµ,maxµ)
6. check the convergence condition
||A−AX−E||∞ < ǫ and ||X− J||∞ < ǫ
end while
The setting of the hyperparameters follows the implementation of 44: Since as
stated in the literature, they are the optimal ones.
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Table 3: The illustration of the LMP algorithm
Algorithm 2: The algorithm of the proposed method
Input: Given an adjacency matrix A
1. compute the low-rank similarity matrix X∗ and
sparse noise E∗ of Eq. (5) by using Algorithm 1
2. compute the similarity matrices ZAD and ZAT by Eq. (6)
3. combine the two similarity matrices as in Eq. (7)
4. sort the scores in ZA in descending order
Output: The highest scores are the most potential interactions
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Table 4: The interaction predicted results measured by AUC and AUPR by 5×10-fold cross
validation for LMP and the benchmark methods. In the first parts only the known interactions are
utilized, while in the second parts characteristic information is also employed. The best performed
results are emphasized in bold.
Dataset MATADOR NR GPCR ion channel enzyme Average
Metric AUC AUPR AUC AUPR AUC AUPR AUC AUPR AUC AUPR AUC AUPR
CN 0.930 0.603 0.688 0.249 0.826 0.491 0.915 0.724 0.910 0.678 0.854 0.549
Katz 0.894 0.393 0.679 0.263 0.800 0.479 0.893 0.707 0.869 0.644 0.827 0.497
Jaccard 0.933 0.612 0.686 0.249 0.828 0.531 0.920 0.680 0.911 0.704 0.856 0.555
CJC 0.930 0.609 0.693 0.265 0.828 0.531 0.914 0.731 0.910 0.673 0.855 0.562
CRA 0.937 0.714 0.696 0.289 0.833 0.565 0.923 0.737 0.912 0.752 0.860 0.612
LMP-ZA 0.946 0.796 0.702 0.276 0.853 0.601 0.941 0.846 0.900 0.766 0.868 0.657
BLM – – 0.694 0.204 0.884 0.464 0.918 0.591 0.928 0.496 0.856 0.439
LapRLS – – 0.855 0.539 0.941 0.640 0.969 0.804 0.962 0.826 0.932 0.702
NetLapRLS – – 0.859 0.563 0.946 0.703 0.977 0.898 0.968 0.874 0.938 0.760
LMP-ZADT – – 0.863 0.513 0.950 0.706 0.979 0.900 0.973 0.875 0.941 0.747
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Table 5: The drug and target predicted results measured by AUC and AUPR by 5×10-fold cross
validation for LMP and the benchmark methods. The best performed results are emphasized in
bold.
Dataset nuclear receptors GPCR ion channel enzyme Average
Metric AUC AUPR AUC AUPR AUC AUPR AUC AUPR AUC AUPR
BLM 0.693 0.194 0.829 0.210 0.770 0.167 0.781 0.092 0.768 0.166
LapRLS 0.820 0.482 0.845 0.397 0.796 0.366 0.800 0.368 0.815 0.403
NetLapRLS 0.819 0.418 0.834 0.397 0.783 0.343 0.791 0.298 0.807 0.364
LMP-ZT 0.831 0.384 0.854 0.399 0.778 0.353 0.824 0.392 0.822 0.382
BLM 0.458 0.325 0.627 0.367 0.881 0.641 0.843 0.611 0.702 0.486
LapRLS 0.563 0.432 0.788 0.508 0.920 0.778 0.914 0.792 0.796 0.628
NetLapRLS 0.561 0.433 0.787 0.503 0.916 0.762 0.909 0.787 0.793 0.621
LMP-ZD 0.688 0.293 0.847 0.583 0.938 0.790 0.928 0.803 0.850 0.617
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